Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25905901 | 0.89 | CRBN (0.49) | CRBNDDB1POLB | |
| SCHEMBL24204275 | 0.85 | CRBN (0.61) | CRBNDDB1POLB | |
| SCHEMBL25567472 | 0.84 | CRBN (0.52) | CRBNDDB1POLB | |
| SCHEMBL25960832 | 0.83 | CRBN (0.46) | CRBNDDB1POLB | |
| SCHEMBL25955979 | 0.83 | CRBN (0.52) | CRBNDDB1POLB | |
| SCHEMBL25905899 | 0.82 | CRBN (0.61) | CRBNDDB1POLB | |
| SCHEMBL24319159 | 0.82 | DDB1 (0.56) | CRBNDDB1POLB | |
| SCHEMBL24204588 | 0.82 | CRBN (0.46) | CRBNDDB1POLB | |
| SCHEMBL24204590 | 0.82 | CRBN (0.46) | CRBNDDB1POLB | |
| SCHEMBL26043193 | 0.82 | CRBN (0.46) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023177451-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | EnhancedBio Inc. (KR) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023109892-A1 | COMPOUND FOR INHIBITING OR DEGRADING BRD9, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023098656-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2023-06-08 | — | — | WO | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | CRBN 3/4885DDB1 362/4885POLB 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.